Veritas In Silico (TYO:130A) has launched its first in-house drug project targeting acute kidney injury after cardiovascular surgery, using an mRNA-targeted nucleic acid drug, according to a Monday filing on the Tokyo Stock Exchange.
The treatment, described as first-in-class, targets high-risk patients aged 65 and older in Japan, with peak domestic sales estimated at 15 billion yen.
Development is estimated within eight to 10 years. The drug will be developed using Veritas' ibVIS platform. The company may commercialize the treatment independently or through licensing.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。